

David E Gerber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6134159/publications.pdf>

Version: 2024-02-01

244
papers

18,631
citations

46918

47
h-index

13727

129
g-index

247
all docs

247
docs citations

247
times ranked

22601
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973
2	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , 2017, 18, 31-41.	5.1	845
3	Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, e173501.	3.4	755
4	Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2010, 85, 838-854.	1.4	517
5	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	0.8	444
6	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	0.8	397
7	Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3307-3315.	0.8	379
8	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	0.8	329
9	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
10	Targeted therapies: a new generation of cancer treatments. <i>American Family Physician</i> , 2008, 77, 311-9.	0.1	255
11	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3824-3830.	0.8	244
12	ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time. <i>Cancer Cell</i> , 2010, 18, 548-551.	7.7	211
13	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156
14	Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 1310-1318.	0.8	140
15	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1363-1372.	0.5	140
16	Development and Validation of a Nomogram Prognostic Model for SCLC Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1338-1348.	0.5	138
17	Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. <i>Seminars in Cancer Biology</i> , 2020, 64, 93-101.	4.3	135
18	The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. <i>Blood</i> , 2008, 112, 504-510.	0.6	128

#	ARTICLE	IF	CITATIONS
19	Immune dysregulation in cancer patients developing immune-related adverse events. <i>British Journal of Cancer</i> , 2019, 120, 63-68.	2.9	126
20	Maintenance Chemotherapy for Advanced Non-Small-Cell Lung Cancer: New Life for an Old Idea. <i>Journal of Clinical Oncology</i> , 2013, 31, 1009-1020.	0.8	125
21	Prevalence of Autoimmune Disease Among Patients With Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1507.	3.4	121
22	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	0.5	119
23	Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer. <i>JAMA Oncology</i> , 2018, 4, 832.	3.4	115
24	Stigma among patients with lung cancer: a patient-reported measurement model. <i>Psycho-Oncology</i> , 2014, 23, 81-92.	1.0	112
25	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	3.2	104
26	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. <i>Cancer Cell</i> , 2016, 30, 940-952.	7.7	104
27	Impact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	95
28	The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. <i>Neuro-Oncology</i> , 2007, 9, 47-52.	0.6	94
29	Targeted Therapies for Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 512-527.	1.0	91
30	BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 992-1001.	1.9	90
31	Predictors and Intensity of Online Access to Electronic Medical Records Among Patients With Cancer. <i>Journal of Oncology Practice</i> , 2014, 10, e307-e312.	2.5	90
32	Effect of Prior Cancer on Outcomes in Advanced Lung Cancer: Implications for Clinical Trial Eligibility and Accrual. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	89
33	A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. <i>Lung Cancer</i> , 2012, 77, 567-571.	0.9	88
34	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 60-67.	0.9	88
35	Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity?. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1322-1330.	0.5	85
36	Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e353-e365.	1.8	75

#	ARTICLE	IF	CITATIONS
37	Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , 2020, 66, 779-793.	1.5	74
38	Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2022-2026.	0.5	73
39	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2500-2518.	3.9	73
40	Phase 1 study of ARQ 761, a Î²-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. <i>British Journal of Cancer</i> , 2018, 119, 928-936.	2.9	66
41	Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 6888-6896.	3.2	64
42	Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. <i>Lancet Respiratory Medicine</i> , 2018, 6, 472-478.	5.2	64
43	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 72-81.	0.4	62
44	Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition. <i>Journal of Thoracic Oncology</i> , 2015, 10, e86-e88.	0.5	60
45	Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e1911519.	2.8	57
46	Targeting the PI3K pathway for cancer therapy. <i>Future Medicinal Chemistry</i> , 2012, 4, 1153-1169.	1.1	53
47	A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). <i>Lung Cancer</i> , 2015, 89, 66-70.	0.9	52
48	Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. <i>British Journal of Cancer</i> , 2017, 116, 717-725.	2.9	52
49	EGFR inhibition in the treatment of non-small cell lung cancer. <i>Drug Development Research</i> , 2008, 69, 359-372.	1.4	51
50	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. <i>Nature Cancer</i> , 2020, 1, 394-409.	5.7	51
51	Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, Î²-lapachone. <i>Scientific Reports</i> , 2015, 5, 17066.	1.6	50
52	Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. <i>Cancers</i> , 2019, 11, 366.	1.7	50
53	Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. <i>Immunotherapy</i> , 2011, 3, 933-944.	1.0	48
54	Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse Population. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1529-1535.	0.5	47

#	ARTICLE	IF	CITATIONS
55	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). <i>Clinical Lung Cancer</i> , 2017, 18, 333-339.	1.1	47
56	ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 447-450.	2.3	46
57	Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1489-1495.	0.5	46
58	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. <i>Cell Reports Medicine</i> , 2020, 1, 100034.	3.3	46
59	Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. <i>Lung Cancer</i> , 2016, 98, 106-113.	0.9	45
60	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status. <i>JAMA Oncology</i> , 2021, 7, 1497.	3.4	45
61	Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 534-541.	0.9	43
62	Socioeconomic Disparities in Lung Cancer Treatment and Outcomes Persist Within a Single Academic Medical Center. <i>Clinical Lung Cancer</i> , 2012, 13, 448-457.	1.1	42
63	Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy. <i>Journal of Thoracic Oncology</i> , 2011, 6, 365-371.	0.5	41
64	NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 2601-2609.	3.2	37
65	Stromal Platelet-Derived Growth Factor Receptor α (PDGFR α) Provides a Therapeutic Target Independent of Tumor Cell PDGFR α Expression in Lung Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2473-2482.	1.9	34
66	Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 644-650.	1.1	34
67	Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2014, 86, 231-236.	0.9	34
68	Should criteria for inclusion in cancer clinical trials be expanded?. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 289-291.	0.6	33
69	ALK alterations and inhibition in lung cancer. <i>Seminars in Cancer Biology</i> , 2017, 42, 81-88.	4.3	33
70	Association between immune-related adverse event timing and treatment outcomes. <i>Oncolmmunology</i> , 2022, 11, 2017162.	2.1	33
71	Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1308-1316.	0.5	32
72	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1357-1362.	0.5	32

#	ARTICLE	IF	CITATIONS
73	Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis. <i>Cancer</i> , 2007, 109, 300-305.	2.0	31
74	Access to Investigational Drugs: FDA Expanded Access Programs or "Right to Try" Legislation?. <i>Clinical and Translational Science</i> , 2015, 8, 526-532.	1.5	31
75	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. <i>Oncolmunology</i> , 2018, 7, e1440168.	2.1	31
76	Optic Neuropathy and Blindness Associated With Crizotinib for Non-Small-Cell Lung Cancer With EML4-ALK Translocation. <i>Journal of Clinical Oncology</i> , 2015, 33, e25-e26.	0.8	30
77	Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases. <i>Clinical Lung Cancer</i> , 2019, 20, e152-e157.	1.1	29
78	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 364-372.	3.2	29
79	Cetuximab in combination therapy: from bench to clinic. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 171-180.	2.7	27
80	A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naïve non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8072-8072.	0.8	25
81	Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 326-332.	0.9	24
82	Increase in Cancer Center Staff Effort Related to Electronic Patient Portal Use. <i>Journal of Oncology Practice</i> , 2016, 12, e981-e990.	2.5	24
83	Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems. <i>Journal of Oncology Practice</i> , 2016, 12, 1020-1028.	2.5	24
84	Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 83-88.	0.8	24
85	Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database. <i>Oncotarget</i> , 2018, 9, 24470-24479.	0.8	24
86	Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer. <i>Patient Education and Counseling</i> , 2012, 89, 102-108.	1.0	23
87	Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies. <i>Lung Cancer</i> , 2015, 87, 232-240.	0.9	23
88	Conceptual Model for Accrual to Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2019, 37, 1993-1996.	0.8	23
89	Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 156-161.	0.5	22
90	Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations. <i>Oncologist</i> , 2015, 20, 674-682.	1.9	21

#	ARTICLE	IF	CITATIONS
91	Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1446-1450.	0.5	21
92	Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1529-1539.	0.6	21
93	Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. <i>Head and Neck</i> , 2019, 41, 1928-1934.	0.9	21
94	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>Oncologist</i> , 2017, 22, 1024-e89.	1.9	20
95	Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer. <i>Oncology</i> , 2020, 98, 179-185.	0.9	20
96	The Impact of Consenter Characteristics and Experience on Patient Interest in Clinical Research. <i>Oncologist</i> , 2009, 14, 468-475.	1.9	19
97	Locally Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 247-262.	1.0	19
98	Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 4252-4259.	2.0	19
99	Chemotherapy for Advanced Non-small Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 119-149.	0.2	18
100	Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 169-176.	1.1	18
101	Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2017, 60, 78-85.	0.8	18
102	How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. <i>Lung Cancer</i> , 2018, 115, 97-102.	0.9	18
103	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. <i>Clinical Cancer Research</i> , 2021, 27, 2416-2423.	3.2	18
104	ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9077-TPS9077.	0.8	18
105	Oncologic emergencies and urgencies: A comprehensive review. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 570-593.	157.7	18
106	Consent Timing and Experience: Modifiable Factors That May Influence Interest in Clinical Research. <i>Journal of Oncology Practice</i> , 2012, 8, 91-96.	2.5	17
107	A Reevaluation of CD22 Expression in Human Lung Cancer. <i>Cancer Research</i> , 2014, 74, 263-271.	0.4	17
108	Hyperprogressive disease: a distinct effect of immunotherapy?. <i>Journal of Thoracic Disease</i> , 2019, 11, S262-S265.	0.6	17

#	ARTICLE	IF	CITATIONS
109	Timing, Sites, and Correlates of Lung Cancer Recurrence. <i>Clinical Lung Cancer</i> , 2020, 21, 127-135.e3.	1.1	17
110	A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrual. <i>BMC Medical Research Methodology</i> , 2020, 20, 123.	1.4	17
111	Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon. <i>Oncologist</i> , 2020, 25, e753-e757.	1.9	17
112	CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e264-e268.	1.1	17
113	Application of Information Technology to Clinical Trial Evaluation and Enrollment. <i>JAMA Oncology</i> , 2021, 7, 1559.	3.4	17
114	Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research Adjustments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 505-512.	2.3	17
115	Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition. <i>Lung Cancer</i> , 2017, 105, 14-16.	0.9	16
116	Characteristics of Patients Using Patient Portals in Oncology. <i>JAMA Oncology</i> , 2018, 4, 416.	3.4	16
117	Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis. <i>Lung Cancer</i> , 2018, 120, 22-26.	0.9	16
118	DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 1449-1459.	3.2	16
119	Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6017-6027.	3.2	16
120	Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. , 2021, 9, e002349.		16
121	Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2169-2181.	2.0	16
122	Recent advances in radiation therapy. <i>American Family Physician</i> , 2008, 78, 1254-62.	0.1	16
123	Mobile Device Applications for Electronic Patient Portals in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-8.	1.0	15
124	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 117, 44-49.	0.9	14
125	Emerging monoclonal antibody therapies for malignant gliomas. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 477-494.	1.9	13
126	Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 817-823.	1.1	13

#	ARTICLE	IF	CITATIONS
127	Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2983-2990.	0.8	13
128	Closing the gap: Contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resection. <i>Cancer Medicine</i> , 2020, 9, 4137-4147.	1.3	13
129	Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9027-9027.	0.8	13
130	Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. <i>Translational Lung Cancer Research</i> , 2019, 8, 202-207.	1.3	12
131	Immunotherapy Use in Patients With Lung Cancer and Comorbidities. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 525-536.	1.0	12
132	Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 493-503.	1.0	12
133	Patient education role of a pharmacist on a transplant service. <i>American Journal of Health-System Pharmacy</i> , 2000, 57, 767-768.	0.5	11
134	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11
135	21st Century Cures Act: Implementation Without Understanding Implication?. <i>JCO Oncology Practice</i> , 2022, 18, 85-87.	1.4	11
136	Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies. <i>Annals of Translational Medicine</i> , 2016, 4, 529-529.	0.7	11
137	Beyond Adenocarcinoma: Current Treatments and Future Directions for Squamous, Small Cell, and Rare Lung Cancer Histologies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 147-162.	1.8	10
138	Cancer Center Clinic and Research Team Perceptions of Identity and Interactions. <i>Journal of Oncology Practice</i> , 2017, 13, e1021-e1029.	2.5	10
139	Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer. <i>Cancer Informatics</i> , 2019, 18, 117693511983754.	0.9	10
140	Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?. <i>Oncologist</i> , 2020, 25, e1242-e1245.	1.9	10
141	Survival of women diagnosed with breast cancer and who have survived a previous cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 853-865.	1.1	10
142	Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9110-9110.	0.8	10
143	Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, 577-579.	1.4	10
144	Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis. <i>Oncology Nursing Forum</i> , 2017, 44, 165-170.	0.5	10

#	ARTICLE	IF	CITATIONS
145	Humoral and cellular correlates of a novel immune-related adverse event and its treatment. , 2021, 9, e003585.		10
146	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer, 2017, 112, 195-199.	0.9	9
147	How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center Experience. PLoS ONE, 2012, 7, e52313.	1.1	9
148	Acute hemolytic transfusion reaction secondary to anti-Fy3. Immunohematology, 2005, 21, 48-52.	0.2	9
149	Implementation and Uptake of Rural Lung Cancer Screening. Journal of the American College of Radiology, 2022, 19, 480-487.	0.9	9
150	Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy. Cancers, 2022, 14, 1327.	1.7	9
151	Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers. Statistics in Medicine, 2018, 37, 2516-2529.	0.8	8
152	Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. Lung, 2019, 197, 593-599.	1.4	8
153	Patient and provider perspectives on delivery of oral cancer therapies. Patient Education and Counseling, 2019, 102, 2102-2109.	1.0	8
154	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical Lung Cancer, 2020, 21, 520-526.	1.1	8
155	Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System. Clinical Lung Cancer, 2021, 22, e612-e620.	1.1	8
156	Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials. Clinical Drug Investigation, 2021, 41, 161-167.	1.1	8
157	Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes. JCO Oncology Practice, 2022, 18, e98-e107.	1.4	8
158	A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).. Journal of Clinical Oncology, 2013, 31, 2507-2507.	0.8	8
159	A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Translational Cancer Research, 2017, 6, S78-S82.	0.4	8
160	Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials. Clinical Lung Cancer, 2017, 18, 626-630.	1.1	7
161	Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?. Journal of Thoracic Oncology, 2019, 14, 332-335.	0.5	7
162	Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. Oncologist, 2020, 25, 515-522.	1.9	7

#	ARTICLE	IF	CITATIONS
163	A novel polymer gel for the delivery of local therapies to intracranial tumors: <i>in vivo</i> safety evaluation. <i>Journal of Biomedical Materials Research - Part A</i> , 2011, 99A, 479-484.	2.1	6
164	Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 580-582.	0.8	6
165	Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial. <i>Clinical Lung Cancer</i> , 2020, 21, 326-332.	1.1	6
166	Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. <i>Cancer</i> , 2020, 126, 1605-1613.	2.0	6
167	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. <i>Cancer Biology and Therapy</i> , 2021, 22, 455-464.	1.5	6
168	Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8095-8095.	0.8	6
169	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. <i>Nature Communications</i> , 2021, 12, 7014.	5.8	6
170	Should family physicians routinely screen for lung cancer in high-risk populations? Yes: CT-based screening is complex but worthwhile. <i>American Family Physician</i> , 2014, 90, 73B-4B.	0.1	6
171	Impact of NCI-Mandated Scientific Review on Protocol Development and Content. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 409-416.	2.3	5
172	Upper lip metastasis of sarcomatoid carcinoma of the lung – an unusual site of disease: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 18.	0.4	5
173	Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines. <i>Journal of Oncology Practice</i> , 2017, 13, e982-e991.	2.5	5
174	Oligometastatic Non-Small-Cell Lung Cancer: How Should We Define and Manage It?. <i>Journal of Oncology Practice</i> , 2018, 14, 32-34.	2.5	5
175	Definition and Coordination of Roles and Responsibilities Among Cancer Center Clinic and Research Personnel. <i>JCO Oncology Practice</i> , 2020, 16, e64-e74.	1.4	5
176	Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. <i>PLoS ONE</i> , 2020, 15, e0231258.	1.1	5
177	Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. <i>Cancer Medicine</i> , 2021, 10, 4752-4767.	1.3	5
178	Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research Adjustments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 505-512.	2.3	5
179	Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population. <i>Clinical Lung Cancer</i> , 2022, 23, 419-427.	1.1	5
180	Statistical justification of expansion cohorts in phase 1 cancer trials. <i>Cancer</i> , 2018, 124, 3339-3345.	2.0	4

#	ARTICLE	IF	CITATIONS
181	QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care. <i>Clinical Lung Cancer</i> , 2020, 21, 21-27.e5.	1.1	3
182	Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. <i>JCO Oncology Practice</i> , 2021, 17, e999-e1011.	1.4	3
183	A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8074-8074.	0.8	3
184	Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100291.	0.6	3
185	Survival of cancer survivors with a new pancreatic cancer diagnosis. <i>Cancer Medicine</i> , 0, , .	1.3	3
186	Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9081-9081.	0.8	3
187	Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 792-799.e4.	2.3	3
188	Choroid plexus papillomaâ€”A case highlighting the challenges of extrapolating pediatric chemotherapy regimens to adult populations. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 170-174.	0.5	2
189	Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer. <i>JAMA Oncology</i> , 2016, 2, 132.	3.4	2
190	Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 666691.	1.3	2
191	Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis. <i>Frontiers in Surgery</i> , 2021, 8, 649531.	0.6	2
192	Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8088-8088.	0.8	2
193	A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21043-e21043.	0.8	2
194	Does decompressive surgery improve outcome in patients with metastatic epidural spinal-cord compression?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 10-11.	2.7	1
195	Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patient. <i>Journal of Radiotherapy in Practice</i> , 2007, 6, 53-57.	0.2	1
196	Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long-term Survivor with Metastatic Nonâ€”Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, e60-e61.	0.5	1
197	Stakeholder engagement to initiate lung cancer screening in an urban safety-net health system. <i>Healthcare</i> , 2020, 8, 100370.	0.6	1
198	Reimbursement Matters. <i>Medical Care</i> , 2021, 59, 461-466.	1.1	1

#	ARTICLE	IF	CITATIONS
199	The role of experience and clinical decision support in clinical trial accrual within oncology.. Journal of Clinical Oncology, 2021, 39, 1527-1527.	0.8	1
200	Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3351-3368.	1.3	1
201	Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers. Cancer Research, 2021, 81, 3441-3443.	0.4	1
202	Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOGâ€ACRIN E2805 trial. Cancer Medicine, 2021, 10, 5917-5924.	1.3	1
203	Abstract 5337: Phase 1 study of bavituximab in advanced solid tumor malignancies: Final results. , 2010, , .		1
204	Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes.. Blood, 2007, 110, 1628-1628.	0.6	1
205	Variation in the assessment of immune-related adverse event occurrence, grade, and timing.. Journal of Clinical Oncology, 2019, 37, 9047-9047.	0.8	1
206	Thyroid dysfunction and immune checkpoint inhibitor outcomes.. Journal of Clinical Oncology, 2020, 38, e15103-e15103.	0.8	1
207	Immune checkpoint inhibition-induced myocarditis in cancer patients: Proposal of a detection and management strategy.. Journal of Clinical Oncology, 2020, 38, e15116-e15116.	0.8	1
208	Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.. Journal of Clinical Oncology, 2020, 38, e21571-e21571.	0.8	1
209	Lung Cancer Computational Biology and Resources. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a038273.	2.9	1
210	Miscellaneous Agentsâ€™Cytotoxics and Hormonal Agents. Journal of Thoracic Oncology, 2012, 7, S387-S389.	0.5	0
211	Simultaneous acute myeloid leukemia and mesothelioma diagnoses in a long-term survivor of the 1984 Bhopal gas leak. Acta OncolÃ³gica, 2014, 53, 984-988.	0.8	0
212	Performance Statusâ€™Based Oncology Practice Guidelines: Easier Said Than Done. Journal of Oncology Practice, 2016, 12, 597-599.	2.5	0
213	Radiation-induced KRAS G12V mutant lung adenocarcinoma in a never smoker. Cancer Treatment Communications, 2016, 7, 8-10.	0.4	0
214	Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?. EBioMedicine, 2020, 60, 103006.	2.7	0
215	Abstract PS11-31: Survival among female breast cancer patients who have survived a previous cancer. , 2021, , .		0
216	Drug exposure: still relevant after all these years. Oncotarget, 2021, 12, 721-722.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies. , 2009, , 321-363.		0
218	Stromal and antitumor effects of BIBF 1120 (nintedanib) in a preclinical lung cancer model.. Journal of Clinical Oncology, 2012, 30, e13563-e13563.	0.8	0
219	The impact of renal function on therapeutic options for advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, e18076-e18076.	0.8	0
220	Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8046-8046.	0.8	0
221	Prevalence and predictors of online patient access to electronic medical records among patients with cancer.. Journal of Clinical Oncology, 2013, 31, 35-35.	0.8	0
222	An Emerging Lung Cancer Biomarker. Science Translational Medicine, 2014, 6, .	5.8	0
223	Finding Needles in the Haystack. Science Translational Medicine, 2014, 6, .	5.8	0
224	Treatment Guidance from the Blood. Science Translational Medicine, 2014, 6, .	5.8	0
225	Exploring the Biology of HPV-Associated Head and Neck Cancer. Science Translational Medicine, 2014, 6, .	5.8	0
226	A New Role for Epigenetic Therapy. Science Translational Medicine, 2014, 6, .	5.8	0
227	Can Milk Do Harm?. Science Translational Medicine, 2014, 6, .	5.8	0
228	An Armored CAR for Leukemia Treatment. Science Translational Medicine, 2014, 6, .	5.8	0
229	MYCing progress against immunosuppression-associated cancers. Science Translational Medicine, 2015, 7, .	5.8	0
230	Some things get better with age. Science Translational Medicine, 2015, 7, .	5.8	0
231	Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2017, 35, 114-114.	0.8	0
232	Underlying host immune dysregulation in cancer patients developing immune-related adverse events.. Journal of Clinical Oncology, 2018, 36, 3030-3030.	0.8	0
233	Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care.. Journal of Clinical Oncology, 2018, 36, e20529-e20529.	0.8	0
234	Mobile device access to electronic patient portals in oncology: Potential implications for patient and practice experiences.. Journal of Clinical Oncology, 2018, 36, 179-179.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials. <i>Blood</i> , 2018, 132, 2267-2267.	0.6	0
236	Expression of soluble DC-HIL/gpnmB receptor in the blood of metastatic non-small cell lung carcinoma treated with anti-PD1/PDL1 monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14038-e14038.	0.8	0
237	Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15126-e15126.	0.8	0
238	Survival among colorectal cancer patients with a history of previous cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16146-e16146.	0.8	0
239	Preventable patient acute mortality after EMR-generated QTc alerts.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19359-e19359.	0.8	0
240	Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3043-3043.	0.8	0
241	Survival among breast cancer patients with a history of previous cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14080-e14080.	0.8	0
242	Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100094.	0.6	0
243	Reply to A. Grand et al. <i>JCO Oncology Practice</i> , 2022, , OP2100821.	1.4	0
244	"Pure and wholesome": Stephen Allen, cholera, and the nineteenth-century New York City water supply. <i>The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha</i> , 2013, 76, 18-27.	0.1	0